Clinical features and related risk factors of chronic hepatitis B patients with concomitant minimal hepatic steatosis

Xiaoyan MA; Yun CHEN; Jiacheng LIU; Jie LI; Chao WU

doi:10.3969/j.issn.1001-5256.2023.01.010

Volume 39 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(1): 63-69

PDF( 2358 KB)

Clinical features and related risk factors of chronic hepatitis B patients with concomitant minimal hepatic steatosis

DOI: 10.3969/j.issn.1001-5256.2023.01.010

Xiaoyan MA¹,
Yun CHEN²,
Jiacheng LIU³,
Jie LI³,
Chao WU^{3
,
,
,}

1.
Nanjing University Medical School, Nanjing 210008, China
2.
Drum Tower Clinical Medical College of Nanjing Medical University, Nanjing 210008, China
3.
Department of Infectious Diseases, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China

Research funding:

National Natural Science Foundation of China General Project (81970545);

National Natural Science Foundation of China General Project (82170609)

More Information

Corresponding author: WU Chao, dr.wu@nju.edu.cn (ORCID: 0000-0002-1657-010X)
Received Date: 2022-07-04
Accepted Date: 2022-09-16
Published Date: 2023-01-20

Abstract

Abstract

Objective To investigate the changes of clinical indices in chronic hepatitis B (CHB) patients with concomitant minimal hepatic steatosis and related factors for minimal hepatic steatosis. Methods A total of 179 CHB patients who underwent liver biopsy in Department of Infectious Diseases, Affiliated Drum Tower Hospital of Nanjing University Medical School, from July 2018 to March 2022 were enrolled, and according to the degree of steatosis, they were divided into non-steatosis group with 98 patients and minimal hepatic steatosis group with 81 patients. Demographic information, clinical data, and liver histopathology data were collected, and related observation indices were compared between the two groups. The independent samples t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between groups. A Spearman correlation analysis was performed, and a Logistic regression analysis was used to investigate the risk factors for minimal hepatic steatosis. Results Compared with the non-steatosis group, the minimal hepatic steatosis group had a significantly higher proportion of male patients (69.1% vs 52.0%, χ²=5.390, P < 0.05) and a significantly higher proportion of patients with significant liver fibrosis (43.2% vs 25.5%, χ²=6.234, P < 0.05). Compared with the non-steatosis group, the minimal hepatic steatosis group had significantly higher levels of body mass index (BMI) (23.61±2.95 kg/m² vs 22.13±2.67 kg/m², t=-4.150, P < 0.05), uric acid (UA) [333.0(291.0-375.5) μmol/L vs 287.5(244.8-345.3) μmol/L, Z=-3.620, P < 0.05], triglyceride [0.92 (0.66-1.14) μmol/L vs 0.77 (0.62-1.02) μmol/L, Z=-2.224, P < 0.05], and controlled attenuation parameter (CAP) [234 (214-258) dB/m vs 218 (201-237) dB/m, Z=-2.867, P < 0.05]. In the group with normal body weight, the patients with minimal hepatic steatosis had significantly higher levels of UA (333.0±63.9 μmol/L vs 291.0±72.8 μmol/L, t=-2.395, P < 0.05) a nd HBV DNA [4.44 (3.51-6.79) log₁₀ IU/mL vs 3.42 (3.00-5.03) log₁₀ IU/mL, Z=-2.474, P < 0.05]. BMI (odds ratio [OR]=1.223, 95% confidence interval [CI] : 1.086-1.378, P=0.001) and UA (OR=1.006, 95%CI: 1.002-1.010, P=0.008) were risk factors for minimal hepatic steatosis in CHB patients, and UA (OR=1.007, 95%CI: 1.001-1.013, P=0.022) was a risk factors for minimal hepatic steatosis in CHB patients with normal body weight. Conclusion Compared with the non-steatosis CHB patients, the CHB patients with minimal hepatic steatosis have a significantly higher proportion of patients with significant liver fibrosis and a significantly higher level of CAP. BMI and UA are independent risk factors for minimal hepatic steatosis in CHB patients, and for the CHB patients with normal body weight, elevated UA is closely associated with the onset of minimal hepatic steatosis.
- Hepatitis B, Chronic,
- Non-alcoholic Fatty Liver Disease,
- Risk Factor

FullText(HTML)

References(26)

References

[1]	LI J, ZOU B, YEO YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398. DOI: 10.1016/S2468-1253(19)30039-1.
[2]	ZHENG Q, ZOU B, WU Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2021, 54(9): 1100-1109. DOI: 10.1111/apt.16595.
[3]	KLEINER DE, BRUNT EM, VAN NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41(6): 1313-1321. DOI: 10.1002/hep.20701.
[4]	WANG MM, WANG GS, SHEN F, et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J]. Dig Dis Sci, 2014, 59(10): 2571-2579. DOI: 10.1007/s10620-014-3180-9.
[5]	SCHEUER PJ. Classification of chronic viral hepatitis: a need for reassessment[J]. J Hepatol, 1991, 13(3): 372-374. DOI: 10.1016/0168-8278(91)90084-o.
[6]	LAI CL, RATZIU V, YUEN MF, et al. Viral hepatitis B[J]. The Lancet, 2003, 362(9401): 2089-2094. DOI: 10.1016/S0140-6736(03)15108-2.
[7]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
[8]	LEE MH, YANG HI, LIU J, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles[J]. Hepatology, 2013, 58(2): 546-554. DOI: 10.1002/hep.26385.
[9]	WONG GL, CHAN HL, YU Z, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B-a prospective cohort study with paired transient elastography examinations[J]. Aliment Pharmacol Ther, 2014, 39(8): 883-893. DOI: 10.1111/apt.12658.
[10]	YEN YH, CHANG KC, TSAI MC, et al. Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease[J]. J Formos Med Assoc, 2018, 117(4): 268-275. DOI: 10.1016/j.jfma.2017.09.002.
[11]	CHEN YC, HSU CW, JENG WJ, et al. Advanced liver fibrosis is associated with necroinflammatory grade but not hepatic steatosis in chronic hepatitis B patients[J]. Dig Dis Sci, 2021, 66(12): 4492-4500. DOI: 10.1007/s10620-020-06761-x.
[12]	SETO WK, FUNG J, CHEUNG KS, et al. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2016, 44(10): 1071-1079. DOI: 10.1111/apt.13804.
[13]	ZHU L, JIANG J, ZHAI X, et al. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study[J]. Liver Int, 2019, 39(1): 70-80. DOI: 10.1111/liv.13933.
[14]	PAIS R, RUSU E, ZILISTEANU D, et al. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease[J]. Eur J Intern Med, 2015, 26(1): 30-36. DOI: 10.1016/j.ejim.2014.12.001.
[15]	NAU AL, SOARES JC, SHIOZAWA MB, et al. Clinical and laboratory characteristics associated with dyslipidemia and liver steatosis in chronic HBV carriers[J]. Rev Soc Bras Med Trop, 2014, 47(2): 158-164. DOI: 10.1590/0037-8682-0009-2014.
[16]	YILMAZ B, KOKLU S, BUYUKBAYRAM H, et al. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis[J]. Afr Health Sci, 2015, 15(3): 714-718. DOI: 10.4314/ahs.v15i3.3.
[17]	CHEN Y, CAO D, LI C, et al. A nomogram for discrimination of non- alcoholic fatty liver disease in patients with chronic hepatitis B[J]. Eur J Gastroenterol Hepatol, 2021, 33(1): 69-75. DOI: 10.1097/MEG.0000000000001691.
[18]	YUAN H, YU C, LI X, et al. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies[J]. J Clin Endocrinol Metab, 2015, 100(11): 4198-4207. DOI: 10.1210/jc.2015-2527.
[19]	HWANG IC, SUH SY, SUH AR, et al. The relationship between normal serum uric acid and nonalcoholic fatty liver disease[J]. J Korean Med Sci, 2011, 26(3): 386-391. DOI: 10.3346/jkms.2011.26.3.386.
[20]	XU CF, YU CH, XU L, et al. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study[J]. PLoS One, 2010, 5(7): e11578. DOI: 10.1371/journal.pone.0011578.
[21]	ZHENG X, GONG L, LUO R, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults[J]. Lipids Health Dis, 2017, 16(1): 202. DOI: 10.1186/s12944-017-0531-5.
[22]	ZHOU M, YANG N, XING X, et al. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease[J]. BMC Gastroenterol, 2021, 21(1): 43. DOI: 10.1186/s12876-021-01615-w.
[23]	PETTA S, CAMMÀ C, CABIBI D, et al. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2011, 34(7): 757-766. DOI: 10.1111/j.1365-2036.2011.04788.x.
[24]	FERNÁNDEZ RODRÍGUEZ CM, ALLER R, GUTIÉRREZ GARCÍA ML, et al. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD)[J]. Rev Esp Enferm Dig, 2019, 111(4): 264-269. DOI: 10.17235/reed.2019.5965/2018.
[25]	BALLESTRI S, NASCIMBENI F, ROMAGNOLI D, et al. The independent predictors of non-alcoholic steatohepatitis and its individual histological features. : Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment[J]. Hepatol Res, 2016, 46(11): 1074-1087. DOI: 10.1111/hepr.12656.
[26]	DUAN H, ZHANG R, CHEN X, et al. Associations of uric acid with liver steatosis and fibrosis applying vibration controlled transient elastography in the united states: a nationwide cross-section study[J]. Front Endocrinol (Lausanne), 2022, 13: 930224. DOI: 10.3389/fendo.2022.930224.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (1770) PDF downloads(153)

Clinical features and related risk factors of chronic hepatitis B patients with concomitant minimal hepatic steatosis

DOI: 10.3969/j.issn.1001-5256.2023.01.010

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical features and related risk factors of chronic hepatitis B patients with concomitant minimal hepatic steatosis

DOI: 10.3969/j.issn.1001-5256.2023.01.010

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content